| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Peroxisome proliferator-activated receptor gamma coactivator 1-alpha;PGC-1-alpha;PPAR-gamma coactivator 1-alpha;PPARGC-1-alpha;Ligand effect modulator 6;PPARGC1A;LEM6, PGC1, PGC1A, PPARGC1; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Gene ID | |
| Host | |
| Immunogen | A synthesized peptide derived from human PGC1 alpha |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-PPARGC1A antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone AOBC-16; isotype Rabbit IgG; reactivity: Human,Mouse,Rat. Reported application contexts include WB (as provided in the source record). Boster Bio Anti-PGC1 alpha PPARGC1A Rabbit Monoclonal Antibody catalog # M00236. Tested in WB application. This antibody reacts with Human, Mouse, Rat.
Key elements and design rationale
- Target: PPARGC1A (Peroxisome proliferator-activated receptor gamma coactivator 1-alpha).
- Antibody format: Monoclonal; clone AOBC-16; isotype Rabbit IgG.
- Host: Rabbit.
- Species reactivity: Human,Mouse,Rat (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
PPARGC1A (protein: P2X purinoceptor 1) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Transcriptional coactivator for steroid receptors and nuclear receptors. Greatly increases the transcriptional activity of PPARG and thyroid hormone receptor on the uncoupling protein promoter. Can regulate key mitochondrial genes that contribute to the program of adaptive thermogenesis. Plays an essential role in metabolic reprogramming in response to dietary availability through coordination of the expression of a wide array of genes involved in glucose and fatty acid metabolism. Induces the expression of PERM1 in the skeletal muscle in an ESRRA-dependent manner. Also involved in the integration of the circadian rhythms and energy metabolism. Required for oscillatory expression of clock genes, such as ARNTL/BMAL1 and NR1D1, through the coactivation of RORA and RORC, and metabolic genes, such as PDK4 and PEPCK. . Reported cellular localization context: Isoform 1: Nucleus. Nucleus, PML body. Tissue expression notes (as provided): Heart, skeletal muscle, liver and kidney. Expressed at lower levels in brain and pancreas and at very low levels in the intestine and white adipose tissue. In skeletal muscle, levels were lower in obese than in lean subjects and fasting induced a 2-fold increase in levels in the skeletal muscle in obese subjects. .
Research relevance and current trends
- Research context keywords from the source record include: Diabetes-associated,Epigenetics and Nuclear Signaling,Fatty Acid Oxidation,Fatty Acids,Heart Disease,Lipid and Lipoprotein Metabolism,Lipids/Lipoproteins,Metabolic Signaling Pathways,Metabolism,Mitochondrial Metabolism,Nuclear Receptors,Nuclear Signaling Pathways,Nucleotide Metabolism,Obesity,Pathways and Processes,Redox Metabolism,Transcription.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
Workflow ideas (metafield): Validate PPARGC1A antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect PPARGC1A expression by Western blot in cell or tissue lysates, Compare relative PPARGC1A levels across experimental conditions (dose/time-course) using antibody-based readouts
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 100-110 kDa; calculated MW: 91027 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 100-110 kDa
- Cellular localization (provided): Isoform 1: Nucleus. Nucleus, PML body.
- Tissue details (provided): Heart, skeletal muscle, liver and kidney. Expressed at lower levels in brain and pancreas and at very low levels in the intestine and white adipose tissue. In skeletal muscle, levels were lower in obese than in lean subjects and fasting induced a 2-fold increase in levels in the skeletal muscle in obese subjects. .
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
